Clinical trials: Actinic Keratoses
Actinic Keratoses, Carcinoma, Squamous Cell
Phase II AK Study in Organ Transplant Patients
The purpose of this study is to determine whether afamelanotide (CUV1647) is effective in reducing the number of actinic keratoses and squamous cell carcinomas developing in immune compromised organ transplant recipients, who are…
- Conditions
- Actinic Keratoses, Carcinoma, Squamous Cell, Organ Transplant Recipients
- Trial name
- NCT00829192
- Testing
- Afamelanotide (CUV1647)
- Where
- 12 sites in Australia, Belgium and 5 more
- Volunteers
- 200 people
- Sponsor
- Clinuvel Pharmaceuticals Limited
Keratosis, Actinic
Maximal Use Systemic Exposure Study of Levulan Kerastick (MUSE 2)
The purpose of this study is to evaluate the potential for systemic exposure of aminolevulinic acid (ALA) and protoporphyrin IX (PpIX) when applied topically under occlusion, in a maximal use setting in patients with multiple…
- Trial name
- NCT02628236
- Testing
- Aminolevulinic Acid (ALA), BLU-U
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- DUSA Pharmaceuticals, Inc.
Actinic Keratosis
Histological Confirmation of Clinical Clearance of Actinic Keratoses Following Treatment With Ingenol Mebutate Gel, 0.05%
The main purpose of this trial is to demonstrate the predictive value of the clinical diagnosis of clearance of Actinic Keratoses after treatment with Ingenol Mebutate using histopathological examination as the standard.
- Trial name
- NCT01892137
- Testing
- Ingenol mebutate gel 0.05%
- Where
- 10 sites in Australia, Germany
- Volunteers
- 137 people
- Sponsor
- LEO Pharma
Actinic Keratoses
Effect of Lipikar Urea 30% Before Actinic Keratoses Treatment
This study is conducted in one center in Germany, in adult subjects having actinic keratoses (grade I or II) lesions on the scalp and meeting specific inclusion/exclusion criteria.
- Trial name
- NCT06274320
- Testing
- Group A: holistic approach, Group B: Tolak® Standard of use
- Where
- Germany
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Cosmetique Active International
Actinic Keratosis
Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses
This research study is being done to compare the safety and effectiveness of GDC 695 (test drug) against the currently marketed reference drug (diclofenac sodium gel, 3%) and to establish that these two drugs work better than…
- Trial name
- NCT02952898
- Testing
- GDC 695, Diclofenac Sodium Gel, 3%, Vehicle gel
- Where
- 16 sites in United States
- Volunteers
- 665 people
- Sponsor
- Balmoral Medical company
Actinic Keratosis
A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Participants With Actinic Keratoses
The purpose of this study it so compare the safety and efficacy profiles of a generic imiquimod 2.5% cream to the reference listed Zyclara® (imiquimod) cream in the treatment of actinic keratosis (AK).
- Trial name
- NCT02120898
- Testing
- Imiquimod, Zyclara®, Vehicle Cream
- Where
- 27 sites in United States
- Volunteers
- 467 people
- Sponsor
- Actavis Inc.
Actinic Keratosis
Potential Effect of Topical Imiquimod on Atrial Ectopy in Patients With Actinic Keratosis
The purpose of this study is to determine the potential effect of topically applied 3.75% imiquimod cream on atrial ectopy in actinic keratosis (AK) patients.
- Trial name
- NCT01413763
- Testing
- Imiquimod cream 3.75%
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Medicis Global Service Corporation
Actinic Keratosis
Biological Effects of LEO 43204 in Actinic Keratosis
This is a Phase I, single-centre, open label, within-subject comparison trial to explore the biological effects of LEO 43204 Gel, 0.037%, applied once daily for 3 consecutive days in patients with actinic keratosis on the upper…
- Trial name
- NCT02600598
- Testing
- LEO 43204 Gel, 0.037%
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- LEO Pharma
Actinic Keratosis
Study to Evaluate the Efficacy, Safety, and Tolerability of Topical VDA-1102 Ointment in Subjects With Actinic Keratosis
This is a Phase 2 clinical study in patients with actinic keratosis involving daily application of 1 of 2 strengths of VDA-1102 topical ointment for approximately 12 weeks (84 days).
- Trial name
- Phase2b (NCT03538951)
- Testing
- 10% VDA-1102, 20% VDA-1102
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- Vidac Pharma
Actinic Keratoses
Multicenter Study to Assess the Efficacy and Safety of Methyl Aminolevulinate Hydrochloride (MAL) 16.8% Cream (CD06809-41) Versus Vehicle Cream for Actinic Keratosis of the Face
A Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study to Assess the Efficacy and Safety of Methyl aminolevulinate hydrochloride (MAL) 16.8% cream (CD06809-41) versus vehicle cream in the treatment of thin and…
- Trial name
- NCT04085367
- Testing
- MAL 16.8% cream, MAL Vehicle Cream
- Where
- 60 sites in United States, Puerto Rico
- Volunteers
- 557 people
- Sponsor
- Galderma R&D
Keratosis
Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Arms and Hands
The purpose of this study is to evaluate the safety and efficacy of imiquimod 5% cream compared to vehicle cream in the treatment of Actinic Keratosis (AK) on the arm and/or hand when the cream is applied once daily 2 days per…
- Trial name
- NCT00115154
- Testing
- Aldara (imiquimod) cream, 5%
- Where
- 18 sites in United States
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- Graceway Pharmaceuticals, LLC
Actinic Keratoses
Treatment of Actinic Keratosis With 5% KOH Solution
This is a prospective single-arm multicenter medical device study to investigate the clinical efficacy and safety of the treatment of actinic keratosis with a 5% potassium hydroxide solution.
- Trial name
- TAKKOH (NCT04024579)
- Where
- 6 sites in Germany
- Volunteers
- 73 people
- Sponsor
- Infectopharm Arzneimittel GmbH
Actinic Keratosis
Cellular and Molecular Events During Treatment of Actinic Keratosis With Imiquimod 5% Cream
Treatment of actinic keratosis with imiquimod cream is expected to cause changes in the genes that are turned on, and turned off, by skin cells.
- Trial name
- NCT00335179
- Testing
- Aldara (imiquimod 5% cream), Vehicle cream
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Graceway Pharmaceuticals, LLC
Actinic Keratosis (AK)
Study of the Photoprotection and Prevention of Actinic Damage With Anthelios Fluide 100 KA+ UVMune 400 in Patients With Multiple Actinic Keratoses
Participants will be invited to take part in a research study as they have been diagnosed with multiple actinic keratosis lesions (AK).
- Trial name
- NCT07335003
- Testing
- Tested product group, Control group
- Where
- Australia
- Volunteers
- 80 people
- Sponsor
- Cosmetique Active International
Actinic Keratoses
Efficacy and Safety of Tixel Treatment on Facial and/or Scalp Actinic Keratoses.
Evaluation of the Efficacy and Safety of a thermal fractional skin treatment system (Tixel) for the treatment of facial and/or scalp actinic keratoses
- Trial name
- NCT05365386
- Testing
- Tixel C
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Novoxel Ltd.
Actinic Keratoses
Safety and Effectiveness Study of Imiquimod Creams for Treatment of Actinic Keratoses (AKs)
The purpose of this study is to determine whether imiquimod creams are effective in treating Actinic Keratoses when applied to the face or balding scalp.
- Trial name
- NCT00605176
- Testing
- imiquimod cream
- Where
- 26 sites in United States
- Volunteers
- 479 people
- Sponsor
- Graceway Pharmaceuticals, LLC
Actinic Keratosis
A Sequential Treatment Regimen of Cryotherapy and Picato® for the Treatment of Actinic Keratosis on the Face and Scalp
The purpose of this trial is to compare the rate of complete clearance of actinic keratosis (AK) using sequential cryotherapy and field treatment with PEP005 Gel compared to cryotherapy alone.
- Trial name
- NCT01541553
- Testing
- Cryotherapy, Vehicle, Ingenol metabute
- Where
- 35 sites in United States
- Volunteers
- 367 people
- Sponsor
- LEO Pharma
Actinic Keratosis
Observational Trial Tolerability and Efficacy of Resiquimod Gel in Patients Treated for Actinic Keratosis.
Determine the recurrence rate of actinic keratosis (AK) lesions in patients with complete clinical clearance at the end of the previous trial SP848-AK-1101 at 6 and 12 months of follow-up.
- Trial name
- NCT01806961
- Where
- 9 sites in Germany, Switzerland
- Volunteers
- 16 people
- Sponsor
- Spirig Pharma Ltd.
Actinic Keratosis
Study To Evaluate The Efficacy And Safety Of Actikerall® Solution In Patients With Grade I-II Actinic Keratoses
The main purpose of this vehicle-controlled study is to determine the efficacy and safety of a solution of Actikerall® (containing 5-fluorouracil 0.5% and salicylic acid 10.0%) in the field-directed treatment of grade I-II…
- Trial name
- NCT02289768
- Testing
- 5-fluorouracil/salicylic acid, Vehicle
- Where
- 14 sites in Germany, United Kingdom
- Volunteers
- 166 people
- Sponsor
- Almirall, S.A.
Actinic Keratosis
Safety and Efficacy Study for the Field-directed Treatment of Actinic Keratosis (AK) With Photodynamic Therapy (PDT)
The purpose of this study is to evaluate the safety and efficacy of BF-200 ALA (Ameluz) versus placebo in the field-directed treatment of mild to moderate actinic keratosis with photodynamic therapy (PDT) when using the…
- Trial name
- NCT01966120
- Testing
- BF-200 ALA gel, Photodynamic therapy with BF-RhodoLED
- Where
- Germany
- Volunteers
- 87 people
- Sponsor
- Biofrontera Bioscience GmbH